Biolyphar

Biolyphar is an early-stage biotechnology company focused on the development of innovative therapies for metabolic diseases, specifically targeting type 2 diabetes and obesity. The company leverages its expertise in medicinal chemistry to design and optimize small molecule candidates that modulate key metabolic pathways. Biolyphar's current research efforts are centered on the development of oral GLP-1 receptor agonists and DPP-4 inhibitors. By focusing on oral delivery, the company aims to improve patient compliance and outcomes compared to existing injectable treatments. Biolyphar is currently in the pre-clinical stage of development, working to advance its lead candidates toward clinical trials.